Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.59 |
| ▸ | CYSLTR1 | Q9Y271 | 7/20 | 0.49 |
| ▸ | GPBAR1 | Q8TDU6 | 7/20 | 0.49 |
| ▸ | CYSLTR2 | Q9NS75 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6027036 | 0.84 | PDE10A (0.59) | PDE10ACYSLTR1GPBAR1CYSLTR2NPC1 | |
| SCHEMBL8802103 | 0.79 | CYSLTR1 (0.64) | PDE10ACYSLTR1GPBAR1CYSLTR2 | |
| SCHEMBL6027127 | 0.77 | KDM4E (0.55) | NPC1RAB9ATP53MAPTMAPK1 | |
| SCHEMBL10686237 | 0.77 | PDE10A (0.68) | PDE10ACYSLTR1GPBAR1CYSLTR2 | |
| SCHEMBL6021515 | 0.75 | RAB9A (0.67) | NPC1RAB9ATP53MAPTMAPK1 | |
| SCHEMBL10662425 | 0.73 | CYSLTR1 (0.61) | PDE10ACYSLTR1GPBAR1CYSLTR2 | |
| SCHEMBL10512475 | 0.72 | PDE10A (0.77) | PDE10ACYSLTR1GPBAR1CYSLTR2 | |
| SCHEMBL10510977 | 0.72 | CYSLTR1 (0.69) | PDE10ACYSLTR1GPBAR1CYSLTR2TP53 | |
| SCHEMBL8799860 | 0.72 | PDE10A (0.60) | PDE10ACYSLTR1GPBAR1CYSLTR2 | |
| SCHEMBL6087603 | 0.70 | CYSLTR1 (0.64) | PDE10ACYSLTR1GPBAR1CYSLTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100076037-A1 | Methods of Treating Neuropathic Pain with Agonists of PPAR-gamma | AESTUS THERAPEUTICS, INC. | 2010-03-25 | — | — | US | claimed |
| EP-2089023-A2 | METHODS OF TREATING NEUROPATHIC PAIN WITH AGONISTS OF PPAR-GAMMA | Aestus Therapeutics, Inc. (US) | 2009-08-19 | — | — | EP | claimed |
| WO-2008063842-A2 | METHODS OF TREATING NEUROPATHIC PAIN WITH AGONISTS OF PPAR-GAMMA | AESTUS THERAPEUTICS, INC. (US) | 2008-05-29 | — | — | WO | claimed |
| EP-1077957-B1 | OXYIMINOALKANOIC ACID DERIVATIVES WITH HYPOGLYCEMIC AND HYPOLIPIDEMIC ACTIVITY | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2004-08-04 | — | — | EP | claimed |
| US-20030186985-A1 | Oxyiminoalkanoic acid derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2003-10-02 | — | — | US | claimed |
| EP-1077957-A1 | OXYIMINOALKANOIC ACID DERIVATIVES WITH HYPOGLYCEMIC AND HYPOLIPIDEMIC ACTIVITY | Takeda Chemical Industries, Ltd. (JP) | 2001-02-28 | — | — | EP | claimed |
| WO-1999058510-A1 | OXYIMINOALKANOIC ACID DERIVATIVES WITH HYPOGLYCEMIC AND HYPOLIPIDEMIC ACTIVITY | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1999-11-18 | — | — | WO | claimed |
| US-20100076037-A1 | Methods of Treating Neuropathic Pain with Agonists of PPAR-gamma | AESTUS THERAPEUTICS, INC. | 2010-03-25 | — | — | US | disclosed |
| EP-2089023-A2 | METHODS OF TREATING NEUROPATHIC PAIN WITH AGONISTS OF PPAR-GAMMA | Aestus Therapeutics, Inc. (US) | 2009-08-19 | — | — | EP | disclosed |
| WO-2008063842-A2 | METHODS OF TREATING NEUROPATHIC PAIN WITH AGONISTS OF PPAR-GAMMA | AESTUS THERAPEUTICS, INC. (US) | 2008-05-29 | — | — | WO | disclosed |
| US-6924300-B2 | Oxyiminoalkanoic acid derivatives | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2005-08-02 | — | — | US | disclosed |
| US-6924300-B2 | Oxyiminoalkanoic acid derivatives | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2005-08-02 | — | — | US | disclosed |
| EP-1077957-B1 | OXYIMINOALKANOIC ACID DERIVATIVES WITH HYPOGLYCEMIC AND HYPOLIPIDEMIC ACTIVITY | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2004-08-04 | — | — | EP | disclosed |
| US-6495581-B1 | DRUG FOR TREATING DIABETES MELLITUS, HYPERLIPEMIA, IMPAIRED GLUCOSE TOLERANCE, ARTERIAL SCLEROSIS AND IMPROVING INSULIN RESISTANCE, INFLAMMATORY DISEASE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2002-12-17 | — | — | US | disclosed |
| US-6495581-B1 | DRUG FOR TREATING DIABETES MELLITUS, HYPERLIPEMIA, IMPAIRED GLUCOSE TOLERANCE, ARTERIAL SCLEROSIS AND IMPROVING INSULIN RESISTANCE, INFLAMMATORY DISEASE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2002-12-17 | — | — | US | disclosed |
| CN-1300285-A | Hydroxyiminoalkanoic Acid Derivatives | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2001-06-20 | — | — | CN | disclosed |
| EP-1077957-A1 | OXYIMINOALKANOIC ACID DERIVATIVES WITH HYPOGLYCEMIC AND HYPOLIPIDEMIC ACTIVITY | Takeda Chemical Industries, Ltd. (JP) | 2001-02-28 | — | — | EP | disclosed |
| EP-1077957-A1 | OXYIMINOALKANOIC ACID DERIVATIVES WITH HYPOGLYCEMIC AND HYPOLIPIDEMIC ACTIVITY | Takeda Chemical Industries, Ltd. (JP) | 2001-02-28 | — | — | EP | disclosed |
| WO-1999058510-A1 | OXYIMINOALKANOIC ACID DERIVATIVES WITH HYPOGLYCEMIC AND HYPOLIPIDEMIC ACTIVITY | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1999-11-18 | — | — | WO | disclosed |
| WO-1999058510-A1 | OXYIMINOALKANOIC ACID DERIVATIVES WITH HYPOGLYCEMIC AND HYPOLIPIDEMIC ACTIVITY | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1999-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030186985-A1 | Oxyiminoalkanoic acid derivatives | GPR119, IRS1, CPT1A | PDE10A 1824/4885CYSLTR1 2672/4885GPBAR1 418/4885 |
| US-20100076037-A1 | Methods of Treating Neuropathic Pain with Agonists of PPAR-gamma | PPARG, PPARA, PPARD | PDE10A 981/4885CYSLTR1 431/4885GPBAR1 76/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.